Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments
Fuyu Zhao,Jianan Zhao,Kai Wei,Ping Jiang,Yiming Shi,Cen Chang,Yixin Zheng,Yu Shan,Yunshen Li,Bingheng He,Mi Zhou,Jia Liu,Li Li,Shicheng Guo,Dongyi He
DOI: https://doi.org/10.2147/itt.s458800
2024-05-17
ImmunoTargets and Therapy
Abstract:Fuyu Zhao, 1– 3, &ast Jianan Zhao, 1– 3, &ast Kai Wei, 1– 3 Ping Jiang, 1– 3 Yiming Shi, 1– 3 Cen Chang, 1– 3 Yixin Zheng, 1– 3 Yu Shan, 1– 3 Yunshen Li, 1– 3 Bingheng He, 4 Mi Zhou, 1, 3 Jia Liu, 1, 3 Li Li, 1, 3 Shicheng Guo, 1 Dongyi He 1– 3 1 Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 3 Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People's Republic of China; 4 Department of Rehabilitation, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dongyi He, Shanghai Guanghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China, Email Psoriasis is a chronic inflammatory skin disease characterized by the excessive proliferation of keratinocytes and heightened immune activation. Targeting pathogenic genes through small interfering RNA (siRNA) therapy represents a promising strategy for the treatment of psoriasis. This mini-review provides a comprehensive summary of siRNA research targeting the pathogenesis of psoriasis, covering aspects such as keratinocyte function, inflammatory cell roles, preclinical animal studies, and siRNA delivery mechanisms. It details recent advancements in RNA interference that modulate key factors including keratinocyte proliferation (Fibroblast Growth Factor Receptor 2, FGFR2 ), apoptosis (Interferon Alpha Inducible Protein 6, G1P3 ), differentiation (Grainyhead Like Transcription Factor 2, GRHL2 ), and angiogenesis (Vascular Endothelial Growth Factor, VEGF ); immune cell infiltration and inflammation (Tumor Necrosis Factor-Alpha, TNF-α ; Interleukin-17, IL-17 ); and signaling pathways ( JAK-STAT , Nuclear Factor Kappa B, NF-κB ) that govern immunopathology. Despite significant advances in siRNA-targeted treatments for psoriasis, several challenges persist. Continued scientific developments promise the creation of more effective and safer siRNA medications, potentially enhancing the quality of life for psoriasis patients and revolutionizing treatments for other diseases. This article focuses on the most recent research advancements in targeting the pathogenesis of psoriasis with siRNA and explores its future therapeutic prospects. Keywords: psoriasis, siRNA, keratinocytes, targeted delivery Psoriasis is a chronic, non-infectious, and disabling disease, with a global prevalence of approximately 2–3% and an increasing incidence over recent years. 1,2 It affects both genders equally, with an average age of onset at 33 years, though it generally occurs earlier in females. 3 Characterized by the excessive proliferation and abnormal differentiation of keratinocytes, along with immune cell infiltration into the epidermis and dermis, this abnormal immune activation leads to the development of raised, scaly, and erythematous skin patches. The pathogenesis of psoriasis remains complex and not yet fully elucidated. Currently, topical and systemic treatments represent the first-line therapeutic approaches for psoriasis. Topical treatments, typically used in the early stages, involve the administration of vitamin D3 or corticosteroids, supplemented by phototherapy. 4 Systemic treatments primarily comprise immunosuppressants, non-specific anti-inflammatory drugs, and molecular targeted therapies. In particular, the introduction of biologics targeting key inflammatory cytokines such as Tumor Necrosis Factor-Alpha ( TNF-α ) and Interleukin-17 ( IL-17 ) has revolutionized the treatment of moderate to severe psoriasis over the past decade. 5 Compared to early-stage treatments, systemic therapies are costlier and may increase the risk of infections. 6,7 The introduction of biologic therapies has markedly improved the treatment of moderate to severe psoriasis. Methods of administration have evolved from subcutaneous delivery to include oral and topical medications. For instance, Tapinarof (an AhR modulator) and Roflumilast (a PDE-4 inhibitor) have demonstrated favorable efficacy and safety outcomes, leading to their approval by the FDA for the topical treatment of plaque psoriasis. 8 Psoriasis still presents many unreso -Abstract Truncated-